Clinical Trials

At Lehigh Valley Health Network, we are committed to providing our patients and community with the best possible care and treatments. Our research scientists are integrated with our clinical departments for a comprehensive, collaborative approach to research. Have a question about clinical trials? Contact the Network Office of Research and Innovation at 610-402-9543.

Showing 90 of 131 Clinical Trials

Clinical Research Trial

Zimmer Knee Study

Randomized Controlled Trial to Compare Persona OsseoTi Keel Cementless TKA vs Persona Keel Cemented TKA  A prospective, multi-center study to demonstrate safety, performance, and clinical benefits of the Persona Keel

Doctor(s) Running This Study
Harry W. Schmaltz, MD
Clinical Research Trial

EA9181

EA9181 A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

EA9181

EA9181 A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

Atrium

Abatacept for Immune Checkpoint Inhibitor associated Myocarditis: A Phase 3, Investigator-initiated, randomized, double-blind, placebo-controlled study to evaluate the Efficacy and safety of Abatacept compared to placebo in hospitalized participants with

Doctor(s) Running This Study
Deborah W. Sundlof, DO
Ranju Gupta, MD
Clinical Research Trial

NRG-GU012 Renal Cancer

NRG-GU012, “Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)”

Doctor(s) Running This Study
Maged F. Khalil, MD
Clinical Research Trial

NRG-GU012 Renal Cancer

NRG-GU012, “Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)”

Doctor(s) Running This Study
Maged F. Khalil, MD